Renal Dose Adjustment (Based on CrCl)
- CrCl 20-50 mL/min: No dose adjustments
- CrCl 20 mL/min: Not indicated
Hepatic Dose Adjustment
- Hepatic impairment: No dose adjustments
See Supplemental Patient Information
- Carefully examine patient's HbA1c, recent blood glucose monitoring data, history of insulin-induced hypoglycemia, current insulin regimen, and body weight before starting pramlintide
- Therapy is contraindicated in patients with poor compliance with current insulin regimen and prescribed self-blood glucose monitoring, HbA1c > 9%, recurrent severe hypoglycemia, presence of hypoglycemia unawareness, confirmed diagnosis of gastroparesis, drugs that stimulate gastrointestinal motility and in pediatric patients
- Therapy is recommended in patients who have failed to achieve adequate glycemic control despite individualized insulin management, and in patients who are receiving ongoing care under the guidance of a physician skilled in the use of insulin and supported by the services of a diabetes educator
- Pramlintide is administered with insulin and is associated with an increased risk of insulin-induced severe hypoglycemia, especially in patients with type 1 diabetes. Severe hypoglycemia associated with therapy may occur and is seen within 3 hours following a pramlintide injection [US Black Box Warning]
- Serious injuries have been reported when severe hypoglycemia has occurred while operating a motor vehicle, heavy machinery, or while engaging in other high-risk activities. However, these risks can be reduced by appropriate patient selection, careful patient instruction, and by insulin dose adjustments [US Black Box Warning]
- Monitor the patient carefully, to reduce the risk of insulin-induced severe hypoglycemia
- Use cautiously in patients with visual or dexterity impairment
- Redness, swelling, or itching at the site of injection have been reported with pramlintide
Cautions: Use cautiously in
- Visual or dexterity impairment
- Concurrent oral drugs requiring rapid onset
Supplemental Patient Information
- Advise patient or caregiver to read patient information leaflet before using the first time and with each refill
- Explain to patient or caregiver how to use home glucose monitoring system and the need for frequent monitoring and recording of blood sugar measurements
Pregnancy Category:C.
Breastfeeding: Safety unknown. Manufacturer recommends administration of pramlintide only if it is determined by the physician that the potential benefit outweighs the potential risk to the infant
Pricing data from www.DrugStore.com in U.S.A.
- SymlinPen 120 1000 MCG/ML SOLN [Box] (AMYLIN PHARMACEUTICALS)
5.4 ml = $461.64
16.2 ml = $1303.71
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
